Skip to Content

Dabigatran Disease Interactions

There are 3 disease interactions with dabigatran:

Major

Dabigatran (Includes dabigatran) ↔ valvular heart disease

Major Potential Hazard, Moderate plausibility. Applies to: Prosthetic Heart Valves

The use of dabigatran for the prophylaxis of thromboembolic events in patients with atrial fibrillation in the setting of other forms of valvular heart disease, including the presence of a bioprosthetic heart valve has not been studied and it is not recommended. The use of dabigatran is contraindicated in patients with mechanical prosthetic valves.

Major

Thrombin inhibitors (Includes dabigatran) ↔ active bleeding

Major Potential Hazard, High plausibility. Applies to: Bleeding, Coagulation Defect

The use of thrombin inhibitors is contraindicated in the presence of active major bleeding. Additionally, these drugs should be used with caution in patients with disease states associated with an increased risk of bleeding.

Moderate

Dabigatran (Includes dabigatran) ↔ renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

The anticoagulant activity and half-life of dabigatran may increase in patients with renal impairment. It is recommended to decrease the dose in patients with severe renal impairment (CrCl 15-30 mL/min). No dose adjustment is recommended in patients with mild or moderate renal impairment. Dosing recommendations for patients with CrCl <15 mL/min or on dialysis has not been established. Care should be exercised when using this agent in patients with renal impairment or on dialysis.

Dabigatran drug interactions

There are 246 drug interactions with dabigatran

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.